Outsee limited

The company's core asset is its proprietary AI engine, Nomaly. This technology takes a 'genomics first' approach, predicting disease and phenotype directly from a single genome. Unlike conventional methods that rely on pattern-matching known genetic associations, Nomaly employs a hypothesis-free, predictive algorithm based on the fundamental principles of molecular and cell biology to uncover the underlying mechanisms that drive disease. A key advantage of this platform is its ability to derive actionable insights from small or previously analyzed datasets, which is particularly valuable for researching rare diseases or extracting new value from existing data.

Outsee's business model centers on leveraging its Nomaly technology for in-house drug target discovery and forming strategic partnerships with pharmaceutical and biotech companies. The company's internal programs are initially focused on complex therapeutic areas such as Central Nervous System (CNS) disorders, rare diseases, and metabolic diseases. Revenue generation is anticipated through collaborations where its platform can accelerate therapeutic discovery and development for its partners. The company has already established partnerships with prominent organizations like Genomics England and FinnGen, applying its technology to large-scale human genome data to identify novel disease targets and biomarkers, with a specific focus on dementia.

Financially, Outsee has demonstrated early traction by securing over £500,000 in precision medicine grants from Innovate UK. In June 2025, the company announced a significant £1.8 million seed funding round led by Ahren Innovation Capital, with participation from Kadmos Capital, Empirical Ventures, and Panacea Ventures. This capital is earmarked for expanding its internal target discovery programs and fostering new industry partnerships, signaling a strategic push towards commercialization and growth.